Cargando…
Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
PURPOSE: We sought to better understand how dose and titration with duloxetine treatment may impact tolerability and treatment discontinuation in patients with major depressive disorder. PATIENTS AND METHODS: We investigated Phase III duloxetine trials. Group 1 was a single placebo-controlled study...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714731/ https://www.ncbi.nlm.nih.gov/pubmed/26811681 http://dx.doi.org/10.2147/NDT.S86598 |
_version_ | 1782410365968056320 |
---|---|
author | Harada, Eiji Shirakawa, Osamu Satoi, Yoichi Marangell, Lauren B Escobar, Rodrigo |
author_facet | Harada, Eiji Shirakawa, Osamu Satoi, Yoichi Marangell, Lauren B Escobar, Rodrigo |
author_sort | Harada, Eiji |
collection | PubMed |
description | PURPOSE: We sought to better understand how dose and titration with duloxetine treatment may impact tolerability and treatment discontinuation in patients with major depressive disorder. PATIENTS AND METHODS: We investigated Phase III duloxetine trials. Group 1 was a single placebo-controlled study with a 20 mg initial dose and a slow titration to 40 and 60 mg. Group 2 was a single study with a 40 mg initial dose and final “active” doses of 40 and 60 mg (5 mg control group), with 1-week titration. Group 3 consisted of eight placebo-controlled studies with starting doses of 40, 60, and 80 mg/day with minimal titration (final dose 40–120 mg/day). Tolerability was measured by rate of discontinuation due to adverse events (DCAE). RESULTS: The DCAE in Group 1 were 3.6% in the 60 mg group, 3.3% in the 40 mg group, and 3.2% in the placebo group. In Group 2, the DCAE were 15.0% in the 60 mg group, 8.1% in the 40 mg group, and 4.9% in the 5 mg group. In Group 3, the DCAE were 9.7% and 4.2% in the duloxetine and placebo groups, respectively. CONCLUSION: This study suggests that starting dose and titration may have impacted tolerability and treatment discontinuation. A lower starting dose of duloxetine and slower titration may contribute to improving treatment tolerability for patients with major depressive disorder. |
format | Online Article Text |
id | pubmed-4714731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47147312016-01-25 Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder Harada, Eiji Shirakawa, Osamu Satoi, Yoichi Marangell, Lauren B Escobar, Rodrigo Neuropsychiatr Dis Treat Original Research PURPOSE: We sought to better understand how dose and titration with duloxetine treatment may impact tolerability and treatment discontinuation in patients with major depressive disorder. PATIENTS AND METHODS: We investigated Phase III duloxetine trials. Group 1 was a single placebo-controlled study with a 20 mg initial dose and a slow titration to 40 and 60 mg. Group 2 was a single study with a 40 mg initial dose and final “active” doses of 40 and 60 mg (5 mg control group), with 1-week titration. Group 3 consisted of eight placebo-controlled studies with starting doses of 40, 60, and 80 mg/day with minimal titration (final dose 40–120 mg/day). Tolerability was measured by rate of discontinuation due to adverse events (DCAE). RESULTS: The DCAE in Group 1 were 3.6% in the 60 mg group, 3.3% in the 40 mg group, and 3.2% in the placebo group. In Group 2, the DCAE were 15.0% in the 60 mg group, 8.1% in the 40 mg group, and 4.9% in the 5 mg group. In Group 3, the DCAE were 9.7% and 4.2% in the duloxetine and placebo groups, respectively. CONCLUSION: This study suggests that starting dose and titration may have impacted tolerability and treatment discontinuation. A lower starting dose of duloxetine and slower titration may contribute to improving treatment tolerability for patients with major depressive disorder. Dove Medical Press 2016-01-11 /pmc/articles/PMC4714731/ /pubmed/26811681 http://dx.doi.org/10.2147/NDT.S86598 Text en © 2016 Harada et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Harada, Eiji Shirakawa, Osamu Satoi, Yoichi Marangell, Lauren B Escobar, Rodrigo Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title | Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title_full | Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title_fullStr | Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title_full_unstemmed | Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title_short | Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
title_sort | treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714731/ https://www.ncbi.nlm.nih.gov/pubmed/26811681 http://dx.doi.org/10.2147/NDT.S86598 |
work_keys_str_mv | AT haradaeiji treatmentdiscontinuationandtolerabilityasafunctionofdoseandtitrationofduloxetineinthetreatmentofmajordepressivedisorder AT shirakawaosamu treatmentdiscontinuationandtolerabilityasafunctionofdoseandtitrationofduloxetineinthetreatmentofmajordepressivedisorder AT satoiyoichi treatmentdiscontinuationandtolerabilityasafunctionofdoseandtitrationofduloxetineinthetreatmentofmajordepressivedisorder AT marangelllaurenb treatmentdiscontinuationandtolerabilityasafunctionofdoseandtitrationofduloxetineinthetreatmentofmajordepressivedisorder AT escobarrodrigo treatmentdiscontinuationandtolerabilityasafunctionofdoseandtitrationofduloxetineinthetreatmentofmajordepressivedisorder |